Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Adaptive Biotechnologies

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT NEO
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
Tickers ADPT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.